Skip to main content
So what do sites need to improve study outcomes?
Scott Gottlieb, the new head of U.S. FDA, has suggested he will promote wider use of adaptive design, and Abi Millar at Pharmaceutical Technology examines whether pharma companies are willing to make the changes to both infrastructure and mindset to allow for more flexible protocols.
Fewer data points will come from the traditional investigator-led EDC data entry process, so what comes next?
I’m honored that the Balance team will be recognized at the 2017 CARE Awards—which celebrate clinical R&D achievements across the life sciences industry—for our innovative work on our randomization and trial supply management (RTSM) technology.